Botulinum Toxin in the Treatment of Chronic Pelvic Pain Syndromes

Botulinum Toxin: Therapeutic Clinical Practice and Science

Volumn , Issue , 2009, Pages 257-273

  Smith, Phillip P ^a   Smith, Christopher P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859083183     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4928-9.00021-4     Document Type: Chapter

References (110)

1. Fall M, Baranowski AP, Fowler CJ, Lepinard V, Malone-Lee JG, Messelink EJ, et al. EAU guidelines on chronic pelvic pain. Eur Urol 2004, 46:681-689.
2. Abrams P, Baranowski A, Berger RE, Fall M, Hanno P, Wesselmann U A new classification is needed for pelvic pain syndromes-are existing terminologies of spurious diagnostic authority bad for patients?. J Urol 2006, 175:1989-1990.
3. Moldwin RM Similarities between interstitial cystitis and male chronic pelvic pain syndrome. Curr Urol Rep 2002, 3:313-318.
4. Smith HS, Audette J, Royal MA Botulinum toxin in pain management of soft tissue syndromes. Clin J Pain 2002, 18(6 suppl):S147-S154.
5. Arezzo JC Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain 2002, 18(6 Suppl):S125-S132.
6. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987, 2:237-254.
7. Giladi N The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 1997, 152:132-135.
8. Kessler KR, Benecke R Botulinum toxin: from poison to remedy. Neurotoxicology 1997, 18:761-770.
9. Cui M, Khanijou S, Rubino J, Aoki KR Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125-133. .11.
10. Aoki KR Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005, 26:785.
11. Mense S Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 2004, 251(suppl 1):I1-I7.
12. Park HJ, Lee Y, Lee J, Park C, Moon DE The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can J Anaesth 2006, 53:470-477.
13. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993, 113:400-404.
14. Rosales RL, Arimura K, Takenaga S, Osame M Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996, 19:488-496.
15. Rand MJ, Whaler BC Impairment of sympathetic transmission by botulinum toxin. Nature 1965, 206:588-591.
16. Nix WA, Butler IJ, Roontga S, Gutmann L, Hopf HC Persistent unilateral tibialis anterior muscle hypertrophy with complex repetitive discharges and myalgia: report of two unique cases and response to botulinum toxin. Neurology 1992, 42(3 Pt 1):602-606.
17. Davis D, Jabbari B Significant improvement of stiff-person syndrome after paraspinal injection of botulinum toxin A. Mov Disord 1993, 8:371-373.
18. Cosgrove AP, Corry IS, Graham HK Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994, 36:386-396.
19. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988, 139:919-922.
20. Brin MF, Vapnek JM Treatment of vaginismus with botulinum toxin injections. Lancet 1997, 349:252-253.
21. Stones W, Cheong Y, et al. Interventions for treating chronic pelvic pain in women. Cochrane Database of Systematic Reviews 2005, 2:CD000387.
22. Doggweiler R, Zerman D, et al. Chronic Spasm of Pelvic Floor Muscles in Patients with Chronic Pelvic Pain. ICS 29th Annual Scientific Meeting, Denver CO, 1999.
23. Brookoff D, Bennett DS Neuromodulation in intractable interstitial cystitis and related pelvic pain syndromes. Pain Med 2006, 7(Suppl 1):S166-S184.
24. Kapural L, Narouze SN, Janicki TI, Mekhail N Spinal cord stimulation is an effective treatment for the chronic intractable visceral pelvic pain. Pain Med 2006, 7:440-443.
25. Updike GM Wiesenfeld HC. Insight into the treatment of vulvar pain: a survey of clinicians. Am J Obstet Gynecol 2005, 193:1404-1409.
26. Smart OC, MacLean AB Vulvodynia. Curr Opin Obstet Gynecol 2003, 15:497-500.
27. Hartmann D, Strauhal MJ, Nelson CA Treatment of women in the United States with localized, provoked vulvodynia: practice survey of women's health physical therapists. J Reprod Med 2007, 52:48-52.
28. Aboseif S, Tamaddon K, Chalfin S, Freedman S, Kaptein J Sacral neuromodulation as an effective treatment for refractory pelvic floor dysfunction. Urology 2002, 60:52-56.
29. Gunter J, Brewer A, Tawfik O Botulinum toxin a for vulvodynia: a case report. J Pain 2004, 5:238-240.
30. Dykstra DD, Presthus J Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. J Reprod Med 2006, 51:467-470.
31. Yoon H, Chung WS, Shim BS Botulinum toxin A for the management of vulvodynia. Int J Impot Res 2007, 19:84-87.
32. Shafik A, El-Sibai O Vaginismus: results of treatment with botulin toxin. J Obstet Gynaecol 2000, 20:300-302.
33. Ghazizadeh S, Nikzad M Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 2004, 104(5 Pt 1):922-925.
34. Everaert K, Devulder J, et al: The Pain Cycle, Implications for the Diagnosis and Treatment of Pelvic Pain Syndromes. ICS 29th Annual Scientific Meeting, Denver CO, 1999.
35. Glazer HI, Jantos M, Hartmann EH, Swencionis C Electromyographic comparisons of the pelvic floor in women with dysesthetic vulvodynia and asymptomatic women. J Reprod Med 1998, 43:959-962.
36. Langford CF, Udvari Nagy S, Ghoniem GM Levator ani trigger point injections: An underutilized treatment for chronic pelvic pain. Neurourol Urodyn 2007, 26:59-62.
37. Romito S, Bottanelli M, Pellegrini M, Vicentini S, Rizzuto N, Bertolasi L Botulinum toxin for the treatment of genital pain syndromes. Gynecol Obstet Invest 2004, 58:164-167.
38. Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol 2004, 44:46-50.
39. Thomson AJ, Jarvis SK, Lenart M, Abbott JA, Vancaillie TG The use of botulinum toxin type A (BOTOX) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles. BJOG 2005, 112:247-249.
40. Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 2006, 108:915-923.
41. Nickel JC, Nyberg LM, Hennenfent M Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology 1999, 54:229-233.
42. Krieger JN, Egan KJ, Ross SO, Jacobs R, Berger RE Chronic pelvic pains represent the most prominent urogenital symptoms of chronic prostatitis. Urology 1996, 48:715-721. discussion 721-722.
43. Collins MM, Stafford RS, O'Leary MP, Barry MJ How common is prostatitis? A national survey of physician visits. J Urol 1998, 159:1224-1228.
44. Zermann DH, Ishigooka M, Doggweiler-Wiygul R, Schubert J, Schmidt RA The male chronic pelvic pain syndrome. World J Urol 2001, 19:173-179.
45. Pontari MA, McNaughton-Collins M, O'Leary MP, Calhoun EA, Jang T, Kusek JW, et al. A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int 2005, 96:559-565.
46. Habermacher GM, Chason JT, Schaeffer AJ Prostatitis/chronic pelvic pain syndrome. Annu Rev Med 2006, 57:195-206.
47. Nickel JC, Alexander RB, Schaeffer AJ, Landis JR, Knauss JS, Propert KJ Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls. J Urol 2003, 170:818-822. Chronic Prostatitis Collaborative Research Network Study Group.
48. Nadler RB, Collins MM, Propert KJ, Mikolajczyk SD, Knauss JS, Landis JR, et al. Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome. Urology 2006, 67:337-342.
49. Yilmaz U, Liu YW, Rothman I, Lee JC, Yang CC, Berger RE Intravesical potassium chloride sensitivity test in men with chronic pelvic pain syndrome. J Urol 2004, 172:548-550.
50. Litwin MS A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index. Urology 2002, 60(6 suppl):14-18. discussion 18-19.
51. Turner JA, Ciol MA, Von Korff M, Berger R Validity and responsiveness of the national institutes of health chronic prostatitis symptom index. J Urol 2003, 169:580-583.
52. Propert KJ, Litwin MS, Wang Y, Alexander RB, Calhoun E, Nickel JC, et al. Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Qual Life Res 2006, 15:299-305.
53. Schneider H, Ludwig M, Weidner W, Brähler E Experience with different questionnaires in the management of patients with CP/CPPS: GPSS, IPSS and NIH-CPSI. World J Urol 2003, 21:116-118. discussion 115.
54. Nickel JC, Johnston B, Downey J, Barkin J, Pommerville P, Gregoire M, et al. Pentosan polysulfate therapy for chronic nonbacterial prostatitis (chronic pelvic pain syndrome category IIIA): a prospective multicenter clinical trial. Urology 2000, 56:413-417.
55. Nickel JC, Forrest JB, Tomera K, Hernandez-Graulau J, Moon TD, Schaeffer AJ, et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. J Urol 2005, 173:1252-1255.
56. Mehik A, Alas P, Nickel JC, Sarpola A, Helström PJ Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology 2003, 62:425-429.
57. Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O'Leary MP, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome. Ann Intern Med 2004, 141:581.
58. Nickel JC, Narayan P, McKay J, Doyle C Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double-blind trial. J Urol 2004, 171:1594.
59. Chuang YC, Yoshimura N, Wu M, Huang CC, Chiang PH, Tyagi P, et al. Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A. Eur Urol 2007, 51:1119-1127.
60. Propert KJ, McNaughton-Collins M, Leiby BE, O'Leary MP, Kusek JW, Litwin MS, et al. A prospective study of symptoms and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome: the National Institutes of Health Chronic Prostatitis Cohort study. J Urol 2006, 175:619-623. discussion 623.
61. Turini D, Beneforti P, Spinelli M, Malagutti S, Lazzeri M Heat/burning sensation induced by topical application of capsaicin on perineal cutaneous area: new approach in diagnosis and treatment of chronic prostatitis/chronic pelvic pain syndrome?. Urology 2006, 67:910-913.
62. Maria G, Destito A, Lacquaniti S, Bentivoglio AR, Brisinda G, Albanese A Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet 1998, 352:625.
63. Maria G, Cadeddu F, Brisinda D, Brandara F, Brisinda G Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin. Curr Med Chem 2005, 12:247-265.
64. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003, 62:259-264. discussion 264-265.
65. Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005, 66:775-779.
66. Kuo HC Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int 2005, 75:170-174.
67. Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 2006, 98:1033-1037. discussion 1337.
68. Park DS, Cho TW, Lee YK, Lee YT, Hong YK, Jang WK Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J 2006, 47:706-714.
69. Zermann D, Ishigooka M, Schubert J, Schmidt RA Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain?. Eur Urol 2000, 38:393-399.
70. Nickel JC Interstitial cystitis: the paradigm shifts: international consultations on interstitial cystitis. Rev Urol 2004, 6:200-202.
71. Bogart LM, Berry SH, Clemens JQ Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. J Urol 2007, 177:450-456.
72. Forrest JB, Nickel JC, Moldwin RM Chronic prostatitis/chronic pelvic pain syndrome and male interstitial cystitis: enigmas and opportunities. Urology 2007, 69(4 suppl):S60-S63.
73. Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg L The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol 1999, 161:553-557.
74. Evans RJ, Sant GR Current diagnosis of interstitial cystitis: an evolving paradigm. Urology 2007, 69(4 Suppl):S64-S72.
75. Peeker R, Fall M Toward a precise definition of interstitial cystitis: further evidence of differences in classic and nonulcer disease. J Urol 2002, 167:2470-2472.
76. Toft BR, Nordling J Recent developments of intravesical therapy of painful bladder syndrome/interstitial cystitis: a review. Curr Opin Urol 2006, 16:268-272.
77. Parsons CL, Stauffer C, Schmidt JD Bladder-surface glycosaminoglycans: an efficient mechanism of environmental adaptation. Science 1980, 208:605-607.
78. Parsons CL, Boychuk D, Jones S, Hurst R, Callahan H Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol 1990, 143:139-142.
79. Sun Y, Keay S, De Deyne PG, Chai TC Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. J Urol 2001, 166:1951-1956.
80. Sun Y, Chai TC Up-regulation of P2X3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis. J Urol 2004, 171:448-452.
81. Maggi CA The dual function of capsaicin-sensitive sensory nerves in the bladder and urethra. Ciba Found Symp 1990, 151:77-83. discussion 83-90.
82. Pezzone MA, Liang R, Fraser MO A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders. Gastroenterology 2005, 128:1953-1964.
83. Wesselmann U Neurogenic inflammation and chronic pelvic pain. World J Urol 2001, 19:180-185.
84. Moldwin RM, Evans RJ, Stanford EJ, Rosenberg MT Rational approaches to the treatment of patients with interstitial cystitis. Urology 2007, 69(4 suppl):S73-S81.
85. Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. Urology 1990, 35:552-558.
86. Hanno PM Analysis of long-term Elmiron therapy for interstitial cystitis. Urology 1997, 49(5A suppl):93-99.
87. Daha LK, Riedl CR, Lazar D, Hohlbrugger G, Pflüger H Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis?. Eur Urol 2005, 47:393-397. discussion 397.
88. Kallestrup EB, Jorgensen SS, Nordling J, Hald T Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol 2005, 39:143-147.
89. Parsons CL Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 2005, 65:45-48.
90. Theoharides TC, Sant GR Hydroxyzine therapy for interstitial cystitis. Urology 1997, 49(5A suppl):108-110.
91. Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol 2003, 170:810-815.
92. Seshadri P, Emerson L, Morales A Cimetidine in the treatment of interstitial cystitis. Urology 1994, 44:614-616.
93. Dasgupta P, Sharma SD, Womack C, Blackford HN, Dennis P Cimetidine in painful bladder syndrome: a histopathological study. BJU Int 2001, 88:183-186.
94. van Ophoven A, Hertle L Long-term results of amitriptyline treatment for interstitial cystitis. J Urol 2005, 174:1837-1840.
95. van Ophoven A, Hertle L The dual serotonin and noradrenaline reuptake inhibitor duloxetine for the treatment of interstitial cystitis: results of an observational study. J Urol 2007, 177:552-555.
96. Rossberger J, Fall M, Peeker R Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis: discomfort, side-effects and treatment outcome. Scand J Urol Nephrol 2005, 39:73-77.
97. Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, et al. A randomized controlled trial of intravesical Bacillus Calmette-Guerin for treatment refractory interstitial cystitis. J Urol 2005, 173:1186-1191.
98. Luo Y A potential modality for interstitial cystitis: intravesical use of anti-inflammatory peptide RDP58. J Urol 2005, 173:340.
99. Payne CK, Mosbaugh PG, Forrest JB, Evans RJ, Whitmore KE, Antoci JP, et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol 2005, 173:1590-1594.
100. Smith CP, Franks ME, McNeil BK, Ghosh R, de Groat WC, Chancellor MB, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003, 169:1896-1900.
101. Smith CP, Vemulakonda VM, Kiss S, Boone TB, Somogyi GT Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A. Neurochem Int 2005, 47:291-297.
102. Vemulakonda VM, Somogyi GT, Kiss S, Salas NA, Boone TB, Smith CP Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol 2005, 173:621-624.
103. Ustinova EE, Gutkin DW, Pezzone MA Sensitization of pelvic nerve afferents and mast cell infiltration in the urinary bladder following chronic colonic irritation is mediated by neuropeptides. Am J Physiol Renal Physiol 2007, 292:F123-F130.
104. Gabella G, Davis C Distribution of afferent axons in the bladder of rats. J Neurocytol 1998, 27:141-155.
105. Huang H, Wu X, Nicol GD, Meller S, Vasko MR ATP augments peptide release from rat sensory neurons in culture through activation of P2Y receptors. J Pharmacol Exp Ther 2003, 306:1137-1144.
106. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004, 172(4 Pt 1):1529-1532.
107. Rapp DE, Turk KW, Bales GT, Cook SP Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006, 175(3 Pt 1):1138-1142.
108. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 2004, 64:871-875. discussion 875.
109. Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005, 65:37-41.
110. Kuo HC Prostate botulinum A toxin injection-an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005, 65:670-674.